Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Organon logo — Here for her health

Organon

Here for her health

Founded 2020 United States Jersey City, United States 6946 employees Post-IPO Debt Total: $1.00B Health Care, Medical Devices +2

General Information

Company Name Organon
Founded Year 2020
Location United States Jersey City, United States
Founders / Decision Makers
Team member
Employees 6946
Industries Health Care, Medical Devices, Pharmaceutical +1
Funding Stage Post-IPO Debt
Business Model B2B, B2C, D2C
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Organon. To contact Organon, visit organon.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Organon compare?

A PDF of Organon and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Organon soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Organon

Organon, founded in 2020 and headquartered in the United States, is a promising player in the global healthcare landscape. Driven by their mission 'Here for her health,' Organon specializes in women's health, biosimilars, and established medicines across a broad spectrum of conditions. The company's commitment to delivering impactful healthcare solutions positions it uniquely within the industry.

With a strategic focus on women’s health, the company is poised for growth in an expanding market that sees increasing demand for specialized healthcare products and services. Their robust portfolio reinforces their competitive edge in the Health Care, Medical Devices, Pharmaceutical, and Women's Health sectors.

Most recently, Organon secured a significant investment with a $1.00B Post-IPO Debt round on 07 May 2024, signifying strong investor confidence and providing essential capital to fuel further initiatives.

Business keywords: Women's Health, Biosimilars, Established Medicines, Reproductive Health, Heart Disease, Dermatology, Allergies, Asthma, Pharmaceuticals, Healthcare Solutions, Therapies, Adverse Event Reporting, Recruitment Fraud Warning

Services & Products

Development and distribution of women's health therapies
General medicines franchise
Healthcare professional support programs
Research and development in women's health

Target Customers

Women at various life stages Healthcare professionals Patients with chronic and acute conditions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $1.00B -
07 May 2024

Organon Alternatives & Competitors

View All Alternatives
Organon vs
UCB
UCB Belgium

We’re #TeamUCB, a global biopharmaceutical company. 💙 Inspired by patients 🔬 Driven by science

IPO
15278 employees
Biotechnology, Health Care
Compare Organon vs UCB
Organon vs
good healthcare group
good healthcare group Germany

Commercial & Operational für Pharma - End-to-End gedacht und umgesetzt

112 employees
Health Care, Pharmaceutical
Compare Organon vs good healthcare group
Organon vs
Genus Pharmaceuticals Ltd
Genus Pharmaceuticals Ltd United Kingdom

Providing comprehensive healthcare solutions with a wide range of generic medicines and pharmacy pro...

22 employees
Health Care, Pharmaceutical
View all alternatives

FAQ About Organon

Here for her health
Organon was founded in 2020.
Organon is headquartered in Jersey City, United States.
Organon operates in Health Care, Medical Devices, Pharmaceutical and Women's Health. Its work centres on Women's Health, Biosimilars, Established Medicines and Reproductive Health. Its customers include Women at various life stages, Healthcare professionals and Patients with chronic and acute conditions.
Organon has a B2B, B2C and D2C business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Organon has approximately 6946 employees.
Organon has completed 1 funding round, raising a total of $1.00B. The latest funding stage is Post-IPO Debt.
Organon offers: Development and distribution of women's health therapies, General medicines franchise, Healthcare professional support programs, Research and development in women's health.
Top alternatives and competitors to Organon include UCB, good healthcare group, Genus Pharmaceuticals Ltd, Gilead Sciences, Jazz Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Organon and UCB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Organon, https://bouncewatch.com/company/organon, updated 27 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes